Italia markets open in 3 hours 10 minutes

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
122,96-3,29 (-2,61%)
Alla chiusura: 04:00PM EST
123,00 +0,04 (+0,03%)
Dopo ore: 07:56PM EST

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

Settore/iHealthcare
SettoreBiotechnology
Impiegati a tempo pieno840

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Douglas S. Ingram Esq.Pres, CEO & Director1,55MN/D1963
Mr. Ian Michael EstepanExec. VP & CFO861,75kN/D1976
Mr. William F. CiambroneExec. VP of Technical Operations780,28kN/D1964
Dr. Louise R. Rodino-Klapac Ph.D.Exec. VP, Chief Scientific Officer and Head of R&D929,68kN/D1978
Mr. Ryan E. BrownSr. VP, Gen. Counsel & Corp. Sec.913,64kN/D1978
Bilal ArifSr. VP of Strategy and OperationsN/DN/DN/D
Mary JenkinsSr. Mang. of Investor RelationsN/DN/DN/D
Ms. Alison NasisiChief People Officer & VPN/DN/DN/D
Dr. Diane L. BerrySr. VP of Global Health Policy and Gov. & Patient AffairsN/DN/DN/D
Mr. Dallan MurraySr. VP & Chief Customer OfficerN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2021 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Sarepta Therapeutics, Inc. al 1 dicembre 2022 è 3. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.